Item 8.01. Other Events.

On September 29, 2009, Endo Pharmaceuticals Solutions Inc., a wholly-owned subsidiary of the Registrant, purchased $48,000,000 aggregate principal amount of Ledgemont PhaRMASM Secured 16% Notes due 2024 (the "Notes") issued by Ledgemont Royalty Sub LLC, Endo Pharmaceuticals Solutions Inc.'s wholly-owned subsidiary. The Notes were purchased subject to a previously announced cash tender offer by Endo Pharmaceuticals Solutions Inc. for any and all outstanding Notes. The tender offer expired on September 24, 2009, at 5:00 p.m., New York City time (the "Expiration Time").

As of the Expiration Time, $48,000,000 Notes had been validly tendered and not withdrawn. Endo Pharmaceuticals Solutions Inc. accepted Notes for payment at a purchase price of $1,000 per $1,000 principal amount, for a total amount of approximately $48,000,000 (excluding accrued and unpaid interest up to, but not including, the payment date for the Notes, fees and other expenses in connection with the tender offer). The aggregate principal amount of Notes accepted for purchase represents approximately 46% of the $105,000,000 aggregate principal amount of Notes that were outstanding prior to the Expiration Time.

Item 9.01. Financial Statements and Exhibits.

(a) Financial Statements of Business Acquired.

Not applicable.

(b) Pro Forma Financial Information.

Not applicable.

(c) Shell Company Transactions

Not applicable.

(d) Exhibits.

Not applicable.

---